期刊文献+

钙敏感受体激活性和失活性突变所致骨矿代谢异常疾病及治疗 被引量:1

Gain and loss-of-function mutations of calcium-sensing receptor associated bone and mineral metabolic disorders and the therapies
下载PDF
导出
摘要 钙敏感受体(calcium-sensing receptor,CaSR)是感知细胞外钙离子浓度,调节甲状旁腺素分泌及尿钙重吸收,维持钙稳态的关键受体。CaSR激活性和失活性突变导致钙调定点的移动,引起相应的钙矿物质代谢异常疾病和骨代谢异常表现。本文综述CaSR突变所致疾病的发病机制、临床表现、治疗策略,通过动物实验模型阐述CaSR的病理生理功能,并探讨针对上述疾病的治疗及CaSR配体药物的研究进展。 Calcium-sensing receptor(CaSR)senses the extracellular calcium concentration,regulates the parathyroid hormone(PTH)secretion,and renal calcium reabsorption,plays an important roles in maintaining the calcium homeostasis.Gain and loss-of-function mutations of CaSR lead to the shift of calcium set-point,and result in the mineral and bone diseases.We reviewed the pathophysiology of diseases associated with activating and inactivating mutations of CaSR,and their clinical characteristics,therapeutic strategy,and animal models.To achieve better understanding of CaSR,the allosteric modulators of CaSR may become promising therapeutic options.
作者 董冰子 李成乾 孙晓方 DONG Bing-zi;LI Cheng-qian;SUN Xiao-fang(Department of Endocrinology and Metabolism,The Affiliated Hospital of Qingdao University,Qingdao 266003,Shandong,China)
出处 《中华骨质疏松和骨矿盐疾病杂志》 CSCD 北大核心 2021年第1期66-74,共9页 Chinese Journal Of Osteoporosis And Bone Mineral Research
基金 国家自然科学基金青年基金(81600691) 中国博士后基金面上项目一等资助(2018M640615)。
关键词 钙敏感受体 家族遗传性低尿钙性高钙血症 常染色体显性遗传性低钙血症 溶钙素 拟钙剂 calcium-sensing receptor familial hypocalciuric hypercalcemia autosomal dominant hypocalcemia calcilytics calcimimetics
  • 相关文献

参考文献2

二级参考文献57

  • 1Brown EM. Role of the calcium-sensing receptor in extracel- lular calcium homeostasis. Best Pratt Res Clin Endocrinol Metab 2013; 27:333-343.
  • 2Kantham L, Quinn S J, Egbuna OI, et al. The calcium-sensing receptor (CaSR) defends against hypercalcemia independent- ly of its regulation of parathyroid hormone secretion. Am J Pls'iol Endoerinol Metab 2009; 297:E915-E923.
  • 3Loupy A, Rmaakrishnan SK, Wootla B, et al. PTH-indepen- dent regulation of blood calcium concentration by the calci- um-sensing receptor. J Clin Invest 2012; 122:3355-3367.
  • 4Freichel M, Zink-Lorenz A, Holloschi A, Hafner M, Flock- erzi V, Raue F. Expression of a calcium-sensing receptor in a human medullary thyroid carcinoma cell line and its contribu- tion to calcitonin secretion. Endoerinolo, 1996; 137:3842- 3848.
  • 5Marie PJ. The calcium-sensing receptor in bone cells: a po- tential therapeutic target in osteoporosis. Bone 2010; 46:571- 576.
  • 6Christopoulos A. Advances in GPCR allostery: from function to structure. Mol Pharmaco12014; 86:463-478.
  • 7Asian D, Andersen MD, Gede LB, et al. Mechanisms for the bone aaaabolic effect of parathyroid homaone treatment in hu- mans. Seand J Clin Lab Invest 2012; 72:14-22.
  • 8Chonchol M, Locatelli F, Abboud HE, et aL A randomized, double-blind, placebo-controlled stndy to assess the efficacy and safety of cinacalcet HCI in participants with CKD not re- ceiving dialysis. Am JKidney Dis. 2009; 53:197-207.
  • 9Fitzpatrick LA, Dabrowski CE, Cicconetti G, et al. Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women. J Bone Miner Res 2012; 27:255-262.
  • 10Fitzpatrick LA, Smith PL, McBride TA, et al. Ronacaleret, a calcium-sensing receptor antagonist, has no significant effect on radial fracture healing time: results of a randomized, dou- ble-blinded, placebo-controlled Phase I1 clinical trial. Bone 201 1 ; 49:845-852.

共引文献39

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部